Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2008, Article ID 164134, 8 pages
http://dx.doi.org/10.1155/2008/164134
Clinical Study

Circulating Tissue Inhibitor of Matrix Metalloproteinase-4 (TIMP-4) in Systemic Sclerosis Patients with Elevated Pulmonary Arterial Pressure

1Cardiology Department, Laikon General Hospital, University of Athens Medical School, 115 27 Athens, Greece
2First Department of Propaedeutic and Internal Medicine, University of Athens Medical School, 115 27 Athens, Greece
3Department of Hygiene and Epidemiology, University of Athens Medical School, 115 27 Athens, Greece
4Pulmonary Unit, Department of Therapeutics, University of Athens Medical School, 115 27 Athens, Greece

Received 31 May 2008; Revised 14 October 2008; Accepted 28 October 2008

Academic Editor: Yona Keisari

Copyright © 2008 Elias J. Gialafos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. P. Denton, C. M. Black, and D. J. Abraham, “Mechanisms and consequences of fibrosis in systemic sclerosis,” Nature Clinical Practice Rheumatology, vol. 2, no. 3, pp. 134–144, 2006. View at Publisher · View at Google Scholar
  2. C. Charles, P. Clements, and D. E. Furst, “Systemic sclerosis: hypothesis-driven treatment strategies,” The Lancet, vol. 367, no. 9523, pp. 1683–1691, 2006. View at Publisher · View at Google Scholar
  3. T. M. Bull, “Screening and therapy of pulmonary hypertension in systemic sclerosis,” Current Opinion in Rheumatology, vol. 19, no. 6, pp. 598–603, 2007. View at Publisher · View at Google Scholar
  4. H. Nagase and K. Brew, “Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors,” Biochemical Society Symposium, no. 70, pp. 201–212, 2003. View at Google Scholar
  5. I. Koskivirta, O. Rahkonen, M. Mäyränpää et al., “Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology,” Histochemistry and Cell Biology, vol. 126, no. 3, pp. 335–342, 2006. View at Publisher · View at Google Scholar
  6. K. Kuroda and H. Shinkai, “Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis,” Archives of Dermatological Research, vol. 289, no. 10, pp. 567–572, 1997. View at Publisher · View at Google Scholar
  7. L. Mattila, K. Airola, M. Ahonen et al., “Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts,” Journal of Investigative Dermatology, vol. 110, no. 4, pp. 416–421, 1998. View at Publisher · View at Google Scholar
  8. J. Greene, M. Wang, Y. E. Liu, L. A. Raymond, C. Rosen, and Y. E. Shi, “Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4,” The Journal of Biological Chemistry, vol. 271, no. 48, pp. 30375–30380, 1996. View at Publisher · View at Google Scholar
  9. J. Fielitz, M. Leuschner, H. R. Zurbrügg et al., “Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis,” Journal of Molecular Medicine, vol. 82, no. 12, pp. 809–820, 2004. View at Publisher · View at Google Scholar
  10. L. E. Felkin, E. J. Birks, R. George et al., “A quantitative gene expression profile of matrix metalloproteinases (MMPS) and their inhibitors (TIMPS) in the myocardium of patients with deteriorating heart failure requiring left ventricular assist device support,” The Journal of Heart and Lung Transplantation, vol. 25, no. 12, pp. 1413–1419, 2006. View at Publisher · View at Google Scholar
  11. B. Stratmann, M. Farr, and H. Tschesche, “MMP-TIMP interaction depends on residue 2 in TIMP-4,” FEBS Letters, vol. 507, no. 3, pp. 285–287, 2001. View at Publisher · View at Google Scholar
  12. M. H. Williams, C. E. Handler, R. Akram et al., “Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension,” European Heart Journal, vol. 27, no. 12, pp. 1485–1494, 2006. View at Publisher · View at Google Scholar
  13. P. P. Sfikakis, M. Kyriakidis, C. Vergos et al., “Diffusing capacity of the lung and nifedipine in systemic sclerosis,” Arthritis & Rheumatism, vol. 33, no. 11, pp. 1634–1639, 1990. View at Publisher · View at Google Scholar
  14. Ch. Kostopoulos, J. Koutsikos, C. Toubanakis et al., “Lung scintigraphy with nonspecific human immunoglobulin G ( T99mC-HIG) in the evaluation of pulmonary involvement in connective tissue diseases: correlation with pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT),” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 2, pp. 343–351, 2008. View at Publisher · View at Google Scholar
  15. I. Moyssakis, E. Gialafos, V. Vassiliou et al., “Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement,” Rheumatology, vol. 44, no. 2, pp. 251–254, 2005. View at Publisher · View at Google Scholar
  16. C. Tei, K. S. Dujardin, D. O. Hodge et al., “Doppler echocardiographic index for assessment of global right ventricular function,” Journal of the American Society of Echocardiography, vol. 9, no. 6, pp. 838–847, 1996. View at Publisher · View at Google Scholar
  17. B. M. McQuillan, M. H. Picard, M. Leavitt, and A. E. Weyman, “Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects,” Circulation, vol. 104, no. 23, pp. 2797–2802, 2001. View at Publisher · View at Google Scholar
  18. D. Mukerjee, D. St. George, C. Knight et al., “Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis,” Rheumatology, vol. 43, no. 4, pp. 461–466, 2004. View at Publisher · View at Google Scholar
  19. E. C. LeRoy, C. Black, R. Fleischmajer et al., “Scleroderma (systemic sclerosis): classification, subsets and pathogenesis,” Journal of Rheumatology, vol. 15, no. 2, pp. 202–205, 1988. View at Google Scholar
  20. A. J. MacGregor, R. Canavan, C. Knight et al., “Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival,” Rheumatology, vol. 40, no. 4, pp. 453–459, 2001. View at Publisher · View at Google Scholar
  21. G. Giannelli, F. Iannone, F. Marinosci, G. Lapadula, and S. Antonaci, “The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension,” Current Medical Research and Opinion, vol. 21, no. 3, pp. 327–332, 2005. View at Publisher · View at Google Scholar
  22. S. Trad, Z. Amoura, C. Beigelman et al., “Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease,” Arthritis & Rheumatism, vol. 54, no. 1, pp. 184–191, 2006. View at Publisher · View at Google Scholar
  23. H. Li, H. Simon, T. M. A. Bocan, and J. T. Peterson, “MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition,” Cardiovascular Research, vol. 46, no. 2, pp. 298–306, 2000. View at Publisher · View at Google Scholar
  24. U. Seeland, I. Kouchi, O. Zolk, G. Itter, W. Linz, and M. Böhm, “Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts,” Journal of Molecular and Cellular Cardiology, vol. 34, no. 2, pp. 151–163, 2002. View at Publisher · View at Google Scholar
  25. D. D. Bonnema, C. S. Webb, W. R. Pennington et al., “Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs),” Journal of Cardiac Failure, vol. 13, no. 7, pp. 530–540, 2007. View at Publisher · View at Google Scholar
  26. M. M. Redfield, R. J. Rodeheffer, S. J. Jacobsen, D. W. Mahoney, K. R. Bailey, and J. C. Burnett Jr., “Plasma brain natriuretic peptide concentration: impact of age and gender,” Journal of the American College of Cardiology, vol. 40, no. 5, pp. 976–982, 2002. View at Publisher · View at Google Scholar
  27. K. T. Spencer, J. N. Kirkpatrick, V. Mor-Avi, J. M. Decara, and R. M. Lang, “Age dependency of the Tei index of myocardial performance,” Journal of the American Society of Echocardiography, vol. 17, no. 4, pp. 350–352, 2004. View at Publisher · View at Google Scholar
  28. Y. Allanore, D. Borderie, J. Avouac et al., “High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis,” Arthritis & Rheumatism, vol. 58, no. 1, pp. 284–291, 2008. View at Publisher · View at Google Scholar
  29. E. Toubi, A. Kessel, G. Grushko, E. Sabo, M. Rozenbaum, and I. Rosner, “The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity,” Clinical and Experimental Rheumatology, vol. 20, no. 2, pp. 221–224, 2002. View at Google Scholar
  30. N. Yazawa, K. Kikuchi, H. Ihn et al., “Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis,” Journal of the American Academy of Dermatology, vol. 42, no. 1, part 1, pp. 70–75, 2000. View at Publisher · View at Google Scholar
  31. G. Giannelli, F. Iannone, F. Marinosci, G. Lapadula, and S. Antonaci, “Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs,” European Journal of Clinical Investigation, vol. 36, supplement 3, pp. 73–77, 2006. View at Publisher · View at Google Scholar
  32. B. Dziankowska-Bartkowiak, E. Waszczykowska, A. Zalewska, and A. Sysa-Jędrzejowska, “Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients,” Mediators of Inflammation, vol. 2005, no. 3, pp. 144–149, 2005. View at Publisher · View at Google Scholar
  33. A. Shahin, A. Elsawaf, S. Ramadan, O. Shaker, M. Amin, and M. Taha, “Serum levels of tissue inhibitors of metalloproteinase 2 in patients with systemic sclerosis with duration more than 2 years: correlation with cardiac and pulmonary abnormalities,” Mediators of Inflammation, vol. 2006, Article ID 38458, 6 pages, 2006. View at Publisher · View at Google Scholar
  34. S. A. Young-Min, C. Beeton, R. Laughton et al., “Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls,” Annals of the Rheumatic Diseases, vol. 60, no. 9, pp. 846–851, 2001. View at Google Scholar
  35. W.-U. Kim, S.-Y. Min, M.-L. Cho et al., “Elevated matrix metalloproteinase-9 in patients with systemic sclerosis,” Arthritis Research & Therapy, vol. 7, no. 1, pp. R71–R79, 2005. View at Publisher · View at Google Scholar
  36. P. P. Sfikakis, B. K. McCune, M. Tsokos, K. Aroni, G. Vayiopoulos, and G. C. Tsokos, “Immunohistological demonstration of transforming growth factor-β isoforms in the skin of patients with systemic sclerosis,” Clinical Immunology and Immunopathology, vol. 69, no. 2, pp. 199–204, 1993. View at Publisher · View at Google Scholar
  37. F. Verrecchia, J. Laboureau, O. Verola et al., “Skin involvement in scleroderma: where histological and clinical scores meet,” Rheumatology, vol. 46, no. 5, pp. 833–841, 2007. View at Publisher · View at Google Scholar
  38. Y.-P. Han, T.-L. Tuan, M. Hughes, H. Wu, and W. L. Garner, “Transforming growth factor-β- and tumor necrosis factor-α -mediated induction and proteolytic activation of MMP-9 in human skin,” The Journal of Biological Chemistry, vol. 276, no. 25, pp. 22341–22350, 2001. View at Publisher · View at Google Scholar
  39. R. T. Schermuly, K. P. Kreisselmeier, H. A. Ghofrani et al., “Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension,” Circulation Research, vol. 94, no. 8, pp. 1101–1108, 2004. View at Publisher · View at Google Scholar
  40. G. Bou-Gharios, J. Osman, C. Black, and I. Olsen, “Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis,” Clinica Chimica Acta, vol. 231, no. 1, pp. 69–78, 1994. View at Publisher · View at Google Scholar
  41. A. Vieillard-Baron, E. Frisdal, S. Eddahibi et al., “Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats,” Circulation Research, vol. 87, no. 5, pp. 418–425, 2000. View at Google Scholar
  42. W. Briest, L. Homagk, H. A. Baba et al., “Cardiac remodeling in erythropoietin-transgenic mice,” Cellular Physiology and Biochemistry, vol. 14, no. 4–6, pp. 277–284, 2004. View at Publisher · View at Google Scholar
  43. C. M. Tummalapalli, B. J. Heath, and S. C. Tyagi, “Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts,” Journal of Cellular Biochemistry, vol. 80, no. 4, pp. 512–521, 2001. View at Publisher · View at Google Scholar
  44. C. A. Fernández and M. A. Moses, “Modulation of angiogenesis by tissue inhibitor of metalloproteinase-4,” Biochemical and Biophysical Research Communications, vol. 345, no. 1, pp. 523–529, 2006. View at Publisher · View at Google Scholar
  45. U. Seeland, C. Haeuseler, R. Hinrichs et al., “Myocardial fibrosis in transforming growth factor-ß1 (TGF-ß1) transgenic mice is associated with inhibition of interstitial collagenase,” European Journal of Clinical Investigation, vol. 32, no. 5, pp. 295–303, 2002. View at Publisher · View at Google Scholar
  46. I. T. W. Harley, K. M. Kaufman, J. M. Guthridge et al., “Whole genome association by DNA pooling leads to interesting candidate genes for systemic sclerosis,” Arthritis & Rheumatism, vol. 56, p. S65, 2007. View at Google Scholar
  47. P. P. Sfikakis and G. C. Tsokos, “Lymphocyte adhesion molecules in autoimmune rheumatic diseases: basic issues and clinical expectations,” Clinical and Experimental Rheumatology, vol. 13, no. 6, pp. 763–777, 1995. View at Google Scholar